A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BioNTech SE
BioNTech SE
Evopoint Biosciences Inc.
Theolytics Limited
Immatics US, Inc.
Bristol-Myers Squibb
Genmab
Imunon
Beijing Biotech
Genmab
National Institutes of Health Clinical Center (CC)
CanariaBio Inc.
Mayo Clinic
AstraZeneca
Incyclix Bio
Compugen Ltd
858 Therapeutics, Inc.
Radiopharm Theranostics, Ltd
AstraZeneca
Terremoto Biosciences Inc.